CA3135592A1 - Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp) - Google Patents

Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp) Download PDF

Info

Publication number
CA3135592A1
CA3135592A1 CA3135592A CA3135592A CA3135592A1 CA 3135592 A1 CA3135592 A1 CA 3135592A1 CA 3135592 A CA3135592 A CA 3135592A CA 3135592 A CA3135592 A CA 3135592A CA 3135592 A1 CA3135592 A1 CA 3135592A1
Authority
CA
Canada
Prior art keywords
alkyl
membered
independently selected
group
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3135592A
Other languages
English (en)
French (fr)
Inventor
Xiaochao Ma
Junjie Zhu
Jie Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CA3135592A1 publication Critical patent/CA3135592A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03044—Xenobiotic-transporting ATPase (3.6.3.44)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CA3135592A 2019-05-20 2020-05-20 Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp) Pending CA3135592A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962850061P 2019-05-20 2019-05-20
US62/850,061 2019-05-20
PCT/US2020/033746 WO2020236901A1 (en) 2019-05-20 2020-05-20 A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)

Publications (1)

Publication Number Publication Date
CA3135592A1 true CA3135592A1 (en) 2020-11-26

Family

ID=73458653

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3135592A Pending CA3135592A1 (en) 2019-05-20 2020-05-20 Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)

Country Status (6)

Country Link
US (1) US12528808B2 (https=)
EP (1) EP3972605A4 (https=)
JP (2) JP7820798B2 (https=)
CN (1) CN114096250B (https=)
CA (1) CA3135592A1 (https=)
WO (1) WO2020236901A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3135592A1 (en) 2019-05-20 2020-11-26 Xiaochao Ma Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
US11813257B2 (en) * 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CN120965522B (zh) * 2025-10-20 2026-02-17 兰树化妆品股份有限公司 一种Fmoc-Tea-OH及其制备方法和在多肽合成中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
US9114102B2 (en) 2007-11-07 2015-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting ABCG2 and related treatments
WO2009088831A2 (en) 2008-01-03 2009-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting abcg2 and other treatment methods
US9056111B1 (en) 2011-09-21 2015-06-16 Stc.Unm Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment
EP3054951A4 (en) * 2013-10-07 2017-05-10 Millennium Pharmaceuticals, Inc. Inhibitor of breast cancer resistance protein (bcrp)
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3341079A4 (en) 2015-08-25 2019-05-08 President and Fellows of Harvard College METHOD AND COMPOSITIONS RELATED TO DIAGNOSIS AND TREATMENT OF CANCER
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
CN106191061B (zh) 2016-07-18 2019-06-18 暨南大学 一种特异靶向人ABCG2基因的sgRNA导向序列及其应用
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
CA3135592A1 (en) 2019-05-20 2020-11-26 Xiaochao Ma Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)

Also Published As

Publication number Publication date
EP3972605A1 (en) 2022-03-30
JP2026027223A (ja) 2026-02-18
US12528808B2 (en) 2026-01-20
WO2020236901A1 (en) 2020-11-26
CN114096250A (zh) 2022-02-25
CN114096250B (zh) 2025-01-14
US20220249473A1 (en) 2022-08-11
JP7820798B2 (ja) 2026-02-26
EP3972605A4 (en) 2023-10-04
JP2022532923A (ja) 2022-07-20

Similar Documents

Publication Publication Date Title
EP2976333B1 (en) Quinolines derivatives as novel anticancer agents
AU2015243379B2 (en) Tubulysin derivatives
JP2026027223A (ja) 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法
EP3341007B1 (en) Malt1 inhibitors and uses thereof
CN118459413A (zh) 用于治疗癌症的组合物和方法
CN110944634A (zh) 用于调节毛发生长的组合物和方法
CN113811333A (zh) 靶向抗癌核激素受体的化合物
WO2020170203A1 (en) Methods of inhibiting kinases
US12377084B2 (en) ERAP1 modulators
WO2017197104A1 (en) Yap1 inhibitors and methods
CN111566113B (zh) 大环化合物及其用途
WO2016044467A1 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
CN109310650A (zh) 用于减少过表达c-myc的癌症中的c-myc的化合物
WO2023220227A1 (en) Treating diseases and disorders with irak4-modifying compounds
US20130345231A1 (en) Anticancer therapeutic agents
AU2012387970A1 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
EP4217361B1 (en) Compounds as modulators of endoplasmic reticulum aminopeptidase 1 (erap1)
CN113710660B (zh) Dot1l降解剂及其用途
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
US12415789B2 (en) Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers
WO2024259442A2 (en) Eupenifeldin derivatives and methods of making and using thereof
CA3037928A1 (en) Combinatory treatment strategies of cancer based on rna polymerase i inhibition
EP4604947A2 (en) Compositions and methods for preventing cardiomyopathy
EP4714444A1 (en) Preparation for and use of cannabidiol derivative drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220907

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250401

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250520

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250718

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250718

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260326

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260326